

§Appl. No. 09/890,654  
Amdt. dated August 10, 2005  
Reply to Office Action February 10, 2005

**Listing of Claims:**

Please **amend** the claims as follows:

**Claim 1 (Cancelled)**

**Claim 2 (Cancelled)**

**Claim 3 (Cancelled)**

**Claim 4 (Cancelled)**

**Claim 5 (Cancelled)**

**Claim 6 (Cancelled)**

**Claim 7 (Cancelled)**

**Claim 8 (Cancelled)**

**Claim 9 (Previously Presented)** A single test kit package for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following components: K1) a solution of a coagulation-inhibiting substance not interfering in the transformation of prothrombin into active meizothrombin or meizothrombin-des fragment 1; K2) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or meizothrombin-des fragment 1; K3) a solution of a substance dissociating prothrombin into meizothrombin or meizothrombin-des fragment 1; and K4) a standard curve for determining the amount of thrombin inhibitor in a sample.

**Claim 10 (Previously Presented)** A single test kit package for determining the activity of thrombin inhibitors in a non-turbid body or in a non-turbid extract from a body liquid or in a non-turbid non-natural aqueous liquid, comprising the following kit components: K1) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or meizothrombin-des fragment 1

§Appl. No. 09/890,654  
Amdt. dated August 10, 2005  
Reply to Office Action February 10, 2005

and; K2) a solution of a substrate dissociating prothrombin into meizothrombin or meizothrombin-des fragment 1; or meizothrombin or meizothrombin-des fragment 1; and K3) a standard curve for determining the amount of thrombin inhibitor in a sample.

**Claim 11 (Cancelled)**

**Claim 12 (Previously Presented)** A test kit according to claim 9, further comprising a solution with prothrombin is provided.

**Claim 13 (Cancelled)**

**Claim 14 (Cancelled)**

**Claim 15 (Previously Presented)** A kit package of claim 9, further comprising meizothrombin or meizothrombin-des fragment 1.

**Claim 16 (Cancelled)**

**Claim 17 (Previously Presented)** A single test kit package for determining the concentration of thrombin inhibitors I a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following components: K1) a solution of a coagulation-inhibiting substance not interfering in the transformation of prothrombin into active meizothrombin or meizothrombin-des fragment 1; K2) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or meizothrombin-des fragment 1; K3) a solution comprising meizothrombin or meizothrombin-des fragment 1; and K4) a standard curve for determining the amount of a thrombin inhibitor in a sample.

§Appl. No. 09/890,654  
Amdt. dated August 10, 2005  
Reply to Office Action February 10, 2005

**Claim 18 (Cancelled)**

**Claim 19 (Previously Presented)** A single test kit package for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following components: K1) a solution of a coagulation-inhibiting substance not interfering in the transformation of prothrombin into active meizothrombin or meizothrombin-des fragment 1; K2) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or meizothrombin-des fragment 1; K3) a solution of a substance dissociating prothrombin into meizothrombin or meizothrombin-des fragment 1; K4) a known amount of hirudin for determining a standard curve.

**Claim 20 (New)** A single test kit package of claim 9, wherein said coagulation-inhibiting substance is a fibrin polymerization inhibiting substance.

**Claim 21 (New)** A single test kit package of claim 20, wherein the fibrin polymerization inhibiting substance is a Gly-Pro-Arg-Pro tetrapeptide.

**Claim 22 (New)** A single test kit package of claim 10, wherein said coagulation-inhibiting substance is a fibrin polymerization inhibiting substance.

**Claim 23 (New)** A single test kit package of claim 22, wherein the fibrin polymerization inhibiting substance is a Gly-Pro-Arg-Pro tetrapeptide.